Epigenetic Regulation of Driver Genes in Testicular Tumorigenesis

don Eyben, Finn E.; Kristiansen, Karsten; Kapp, Daniel S.; Hu, Rong; Preda, Ovidiu; Nogales, Francisco F.

Published in: International Journal of Molecular Sciences

DOI: 10.3390/ijms24044148

Publication date: 2023

Document version Publisher's PDF, also known as Version of record

Document license: CC BY


Download date: 27. sep., 2023
Epigenetic Regulation of Driver Genes in Testicular Tumorigenesis

Finn E. von Eyben 1,*, Karsten Kristiansen 2,3,4, ©, Daniel S. Kapp 5, Rong Hu 6, Ovidiu Preda 7 and Francisco F. Nogales 8

1 Center for Tobacco Control Research, Birkevej 17, 5230 Odense, Denmark
2 Laboratory of Genomics and Molecular Biomedicine, August Krogh Building Department of Biology, University of Copenhagen, Universitetsparken 13, 2100 Copenhagen, Denmark
3 BGI-Research, BGI-Shenzhen, Shenzhen 518120, China
4 Institute of Metagenomics, Qingdao-Europe Advanced Institute for Life Sciences, BGI-Qingdao, Qingdao 166555, China
5 Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA
6 Department of Pathology, Laboratory Medicine, University of Wisconsin Hospital and Clinics, Madison, WI 53792, USA
7 Department of Pathology, San Cecilio University Hospital, 18071 Granada, CP, Spain
8 Department of Pathology, School of Medicine, University Granada, 18071 Granada, CP, Spain
© Correspondence: finn113edler@mail.tele.dk; Tel.: +45-66145862

Abstract: In testicular germ cell tumor type II (TGCT), a seminoma subtype expresses an induced pluripotent stem cell (iPSC) panel with four upregulated genes, OCT4/POU5F1, SOX17, KLF4, and MYC, and embryonal carcinoma (EC) has four upregulated genes, OCT4/POU5F1, SOX2, LIN28, and NANOG. The EC panel can reprogram cells into iPSC, and both iPSC and EC can differentiate into teratoma. This review summarizes the literature on epigenetic regulation of the genes. Epigenetic mechanisms, such as methylations of cytosines on the DNA string and methylations and acetylations of histone 3 lysines, regulate expression of these driver genes between the TGCT subtypes. In TGCT, the driver genes contribute to well-known clinical characteristics and the driver genes are also important for aggressive subtypes of many other malignancies. In conclusion, epigenetic regulation of the driver genes are important for TGCT and for oncology in general.

Keywords: differentiation; epigenetics; LIN28; NANOG; POU5F1; SOX2; testis cancer

1. Introduction: Epigenetics, Differentiation, and Testicular Germ Cell Tumors

In 1957, Waddington described an epigenetic landscape of differentiation where a one-way road leads totipotent stem cells over pluripotent stem cells to unipotent differentiated cells (Figure 1a) [1]. Later studies show that gene panels are able to reprogram unipotent differentiated cells into induced pluripotent stem cells (iPSC) [2,3]. An iPSC panel includes POU5F1 and SOX2, combined with LIN28 and NANOG (the Thomson OSLN panel) [2]. A second iPSC panel includes POU5F1 and SOX2, combined with KLF4 and MYC (the Yamanaka OSKM panel) [3]. iPSC can differentiate into teratoma (TER) [4]. The iPSC concept represents a major paradigm shift which points to a bi-directional two-way road for differentiation in the Waddington landscape.

Two precursor lesions for testicular germ cell tumors type II, germ cell neoplasia in situ (GCNIS) and microinvasive germ cell tumor (MGCT) (Figure 1b) [5,6], and seminoma (SE) also express an OSKM panel, with SOX17 as substitute for SOX2. In SE, SOX17 stimulates genes that inhibit differentiation [7] but allows SE to be transformed into embryonal carcinoma (EC) [8]. EC is the undifferentiated nonseminomatous (NST) subtype of testicular germ cell tumors type II. The transformation includes a shift from a highly expressed SOX17 in SE to a highly expressed SOX2 in EC and a shift from the OSK to the OSLN panel [9]. The iPSC panels are driver genes in the tumorigenesis of testicular germ cell tumors type II.
EC highly expresses the OSLN panel (Figure 1c) [6]. EC can differentiate both into an embryonic subtype, TER, and into two extra-embryonic subtypes, yolk sac tumor (YST), and choriocarcinoma (CC) (Figure 2a) [6]. As EC differentiates into TER, the OSLN panel is silenced (Figure 1a). As proof of principle for the Waddington landscape has a two-way road of differentiation, Eldar-Geva et al. reported that fibroblasts from a 32-year-old SE patient were reprogrammed into iPSC [10]. A circuit of OCT4, SOX2, and NANOG is crucial for the tumorigenesis of testicular germ cell tumors type II [11]. One of the authors of this review (FFN) was the first to argue that iPSC is crucial for some patients with EC [12].

(a)

Figure 1. Cont.
Figure 1. Cont.
Figure 1. TGCT subtypes in the tumorigenesis of TGCT. (a). The epigenetic landscape for germ cells. The germ cells progress from toti-differentiated cells to unipotent cells, and a gene panel of \textit{OCT4}, \textit{SOX2}, \textit{LIN28}, and \textit{NANOG} (OSLN) can reprogram germ cells for induced pluri- to totipotent stem cells (iPSC). The red boxes show gene panels for iPSC. The progression of the TGCT subtypes implies a loss of chromosomes from tetraploid malignant germ cells over hypertriploid seminoma to hypotriploid embryonic carcinoma. (b). Microinvasive germ cell tumor (MGCT). MGCT is the first invasive step in the tumorigenesis of TGCT. MGCT is an intermediary precursor of TGCT that has malignant germ cells inside and outside seminiferous tubules in the testis. The figure shows MGCT stained for \textit{OCT4}, the protein of \textit{POU5F1}. (c). Embryonal carcinoma (EC). EC has a positive homogeneous immunohistochemical staining for three transcription factors for induced pluripotent stem cells (OCT4, SOX2, and NANOG) and a homogeneous negative staining for the protein of the tumor suppressor gene, \textit{RB1}. EC stained immunohistochemically positive for OCT4 (1c1), SOX2 (1c2), LIN28 (1c3), and immunohistochemically negative for RB1 (1c4).
Figure 2. Cont.
<table>
<thead>
<tr>
<th>Subtype</th>
<th>Gene Expression</th>
</tr>
</thead>
<tbody>
<tr>
<td>SE</td>
<td>OCT4, SOX2, SOX17, KLF4, MYC, LIN28, NANOG</td>
</tr>
<tr>
<td>EC</td>
<td>OCT4, SOX2, SOX17, KLF4, MYC, LIN28, NANOG</td>
</tr>
<tr>
<td>TER</td>
<td>OCT4, SOX2, SOX17, KLF4, MYC, LIN28, NANOG</td>
</tr>
</tbody>
</table>

(c)

**Figure 2.** Development of normal and malignant testicular germ cells. (a) Shows the development of normal testicular germ cells from fetal life to spermatogenesis in adulthood, and the development of malignant testicular germ cells from tetraploid malignant germ cells to the testicular germ cell tumors type II subtypes. Seminomas are diagnosed at a higher age than non-seminomatosus testicular germ cell tumors as reflection of a lower proliferation rate in seminoma. (b) Chromosome 12. The short arm of chromosome 12 (12p) has two candidate regions that are especially important for the tumorigenesis of testicular germ cell tumors type II, shown in red. The candidate regions have gene loci for three driver genes: CCND2, NANOG and LDHB. The candidate regions are shown in red. The figure also shows other genes that literature and OMIM relate to TGCT. (c) IPSC gene panel in TGCT subtypes. The combined OSKM/OSLN panels for seminoma, embryonal carcinoma, and teratoma have dramatic differences with up- and down-regulations of the genes. Down-regulated genes are indicated with red and up-regulated genes are indicated with green.

In this review of the tumorigenesis of TGCT, we examine whether DNA methylations and histone modifications modify the expression of driver genes between the subtypes of testicular germ cell tumors type II, and whether epigenetic writers, readers, and erasers modulate the modifiers.

2. Testicular Germ Cell Tumors Type II

2.1. Pathology

There are seven types of testicular germ cell tumors [13]. Testicular germ cell tumors type I are tumors in early infancy. Testicular germ cell tumors type II (denoted TGCT in our review) have two main groups where patients with SE are diagnosed at a median age of 35 years and patients with NST are diagnosed at a median age of 25 years. Type III consists of spermatocytic tumor (ST). Patients with ST had a median age > 50 years. Type IV and V are mainly female germ cell tumors. Type VI are germ cell tumors that arise due to reprogramming for iPSC.

TGCT is unique in oncology. Of the seven germ cell tumor types, only TGCT originates from GCNIS, first described by Wilms in 1896 [14]. In oncology, only EC develops into TER. TGCT has a pathognomonic genetic abnormality, an isochromosome of the short arm of chromosome 12, i(12p) [15–19]. TGCT has a unique network with downregulated CDKN2A (p16(INK4a), CDKN2C (p18(INK4c), CDKN2D (p19(INK4d))), and CDKN1A (p21, CIP1, WAF1), upregulated CCND2, and downregulated RB1 [20]. The genes synergistically inhibit suppression of proliferation.

Compared with other malignancies, patients with TGCT have a unique isoenzyme pattern for serum lactate dehydrogenase (S-LDH) with an unusually high LDH isoenzyme 1 activity (S-LDH-1) [21–23]. LDH-1 is a tetramer of four LDHB subunits, generated from LDHB on the short arm of chromosome 12, 12p [24]. Of all malignancies, the international tumor, nodes, and metastases (TNM) classification incorporates serum tumor markers only for TGCT [25]. The serum tumor markers are serum alpha fetoprotein (S-AFP), serum human chorionic gonadotropin (S-hCG), and S-LDH. The classification was adopted from
a study by the International Germ Cell Consensus Classification Group [26]. Metastatic TGCT responds extraordinarily well to platin-based chemotherapy, so Einhorn called TGCT a model of a curable solid neoplasm [27].

For young adult Caucasian men, TGCT is the most frequent malignancy, and the incidence has increased worldwide in many recent decades [28–30].

The TGCT subtypes differ in frequency. For 78% of tests with TGCT, GCNIS is present in the testis besides the TGCT [31]. A Danish Testis Cancer (DATECA) group study reported a five-year nation-wide cohort of patients with TGCT where a central review reevaluated the TGCT histology according to a World Health Organization (WHO) classification [32]. The cohort included 1058 patients. Half of the patients had SE, slightly less than half of the patients had NST (including those with both SE and NST), and one percent of the patients had ST. Of the NST patients, three quarters of the patients had an EC component in the tumors, half the patients had a TER component, and less than a quarter of the patients had a YST component or a CC component. The patients were followed with regular monitoring of S-AFP and S-hCG [33]. The serum tumor markers were important for staging and outcome of treatment.

2.2. Tumorigenesis

As background for TGCT, endogenous androgen levels during puberty and early adulthood are inversely associated with the risk of TGCT [34]. Severe acne reduced the risk of TGCT with 50%. TGCT develops from normal germ cells through precancer lesions and subclinical precursor lesions to macroscopically overt tumors (Figure 2a) [35–39]. On ultrastructural level, testicular malignant germ cells resemble spermatogonia type A more than gonocytes [40].

2.3. Cytogenetics

The TGCT tumorigenesis is governed by cytogenetic abnormalities. To illustrate the cytogenetic abnormalities, long-term cultures of primordial germ cells gradually increase the copy number of chromosome 12, 17, and X, similar to the pattern in TGCT [41–45]. Walt et al. found that tetraploidization is the first step in the TGCT tumorigenesis [46]. Testicular germ cells have several ways to tetraploidization. Cells that are deficient in CDKN1A (p21/Cip1) can bypass a G2 block and conduct a second S phase before they undergo mitosis [47]. TGCT has deregulated AURKA, AURKB, and AURKC, that may lead to abnormal chromosomal segregation and cytogenesis during cell divisions [48,49]. Later, malignant tetraploid germ cells loose chromosomal material [37]. In consequence, SE consists of hypertriploid cells and NS of hypotriploid cells [36]. GCNIS and SE have a higher ploidy than NST [50,51].

Comparative genomic hybridization of TGCT shows the tumors have gains of parts of chromosome 7, 8, 12p, 14, and X, and losses of parts of chromosomes 3, 4, 5, 10, 11, 12q, 16, 18, 22, and Y [52].

Of the TGCT subtypes, only a minority of SE patients have KIT, KRAS2, and NRAS mutations [51]. SE has a rate of 0.06 mutations/Mb [53]. TGCT has a rate of 0.5 mutations/Mb whereas other malignancies have mutation rates of 4.0 mutations/Mb [54].

2.4. Genetics

The TGCT subtypes differ in gene expression and the differences contribute to the TGCT tumorigenesis [55]. Two regions of chromosome 12p are important for the tumorigenesis (Figure 2b) as the regions have gene loci for NANOG, CCND2, LDHB, and KRAS2. DNA methylation increases in the progression from GCNIS to differentiated NST subtypes [56–59].

The gene expression of the OSLN/OSKM panels changes dramatically as SE develops into EC and TER (Figure 2c) [6]. Thus, POLISF1/OCT4, SOX17, SOX2, KLF4, MYC, LIN28, and NANOG are driver genes for TGCT. Other driver genes in undifferentiated
TGCT subtypes are upregulated oncogenes CCND2 [60], KLF4 [61], and MYC [62] and a downregulated tumor suppressor gene RB1 [63]. Many candidate genes for TGCT have their gene locus on chromosomes other than the short arm of chromosome 12 (12p). AFP has gene locus on 4q13.3, TET2 on chromosome 4q24, SOX17 on 8q11.23, MYC on 8q14.13, POU5F1 on 8q24, KLF4 on 9q31.2, RB1 on 13q14.2, CCGB3 on 19q13.33, and DNMT3B on 20q11.1. Similarities and differences in expression of the driver genes between the TGCT subtypes form a biologic chain for the TGCT tumorigenesis. The OSLN/OSK panels change dramatically in expression as SE progresses to EC and TER (Figure 2b). Environmental factors regulate gene expressions in TGCT through a KIT/KITL signal transduction pathway [64]. Normal germ cells express PRAME and LDHC, the gene for the subunit of a testis specific lactate dehydrogenase isoenzyme, LDH-C [65–67], but not KIT and NANOG. Normal germ cells, GCNIS, and SE express PRAME but not NST [68–70]. GCNIS expresses PRAME, KIT, and NANOG but not LDHC. Normal male germ cells express RBMY1A, whereas the gene is silenced in SE and EC [71]. GCNIS and embryonic stem cells have similar gene expressions [72–74]. In GCNIS, POU5F1, NANOG, SOX17, LIN28, and KIT were among the twenty genes with the highest gene expression. Invasion as GCNIS progresses to MGCT is associated with i (12p) [75,76], downregulated CDKN1A (p21), and upregulated MDM2 [77]. SE highly expresses POU5F1 [78–80]. Microenvironment factors such as TGF-beta, EGF, and FGF4 support the transition from TCam-2 to EC [81]. The development from the SE expression of SOX17 to the EC expression of SOX2 is part of the iPSC changes between the TGCT subtypes (Figure 2c) [82]. The changes show TGCT has a cellular plasticity. SE has OCT4 and SOX17 as partners, and EC has OCT4 and SOX2 as partners [7]. NANOG is not expressed in normal testicular germ cells, highly expressed in SE and EC, and silenced in YST, CC, and TER. Moreover, SE and EC overexpress POU5F1 and NANOG whereas TER does not [82]. EC and YST highly express the NODAL co-receptor CRRIPTO and GCNIS, SE, and CC have a lower expression [83]. Immunohistochemistry links AFP in NST in patients to S-AFP [84] and links hCG in TGCT in patients to S-hCG [85]. Retinoic acid stimulates EC to differentiate into TER. The differentiation is associated with downregulated POU5F1 leading to downregulated PUMA and NOXA and reduced apoptosis [86].

3. Epigenetics and TGCT
3.1. Tumorigenesis
The TGCT tumorigenesis is also governed by epigenetics. Epigenetic regulation of genes in iPSC panels is important for the similarity between embryonic stem cells (ESC) and EC [87]. Normal germ cell tissue and TGCT subtypes differ in epigenetics [57]. Normal tissues have imprinted genes and methylated LINE1 and Alu elements in the DNA string whereas both SE and NST have unmethylated LINE1. SE has unmethylated Alu elements whereas NST has methylated Alu elements. TGCT expresses TET1 and the thymine DNA glycosylase TDG supporting that TGCT demethylate methylated DNA using an oxidative pathway [88]. MiR-223-3p regulates TGCT growth and apoptosis [89]. Of the TGCT precursors, GCNIS expresses DNMT1 and has generally hypomethylated DNA. GCNIS had elevated H2A.Z, mono-, di-, and trimethylated histone 3 lysine 4 (H3K4me1, H3K4me2, and H3K4me3) and H3K9me2, and acetylated histone 3 lysine 9 (H3K9ac), and low H3Kme2 and H3K9me2 [90,91]. In GCNIS, hypomethylation is not solely due to lack of demethylation. Regarding demethylation, GCNIS does not have the methylcytosine dioxygenases TET1 and TET2, so GCNIS uses an AID/APOBEC1 pathway for the demethylation [90]. Of TGCT subtypes, SE had elevated H3K4me1 and H3K9me2 and low H3K4me2, H3K4me3, H3K9ac, and H3K27me3. In SE, an OCT4/SOX17 complex binds to a compressed
motif CTTTGTTATAAAT \[92\]. The SOX2 promoter has H3K27me3 and polycomb complex 2 and suppresses SOX2 \[93\]. Further in SE, the compressed motif together with other OSKM genes hinder differentiation of SE and gives SE a poised pluripotency. In malignant germ cells, the canonical motif is located in enhancers of genes for pluripotency whereas the compressed motif is located in regulatory regions of genes for differentiation into endodermal structures. TGCT expresses HDAC1, HDAC2, and HDAC3, where CC has a high HDAC2 \[94\].

TCam-2, a SE cell type, does not express SOX2 \[93,95\]. TCam-2 has elevated H3K4me3 and H3K27ac for SOX17 and low H3K4me3 and H3K27ac for SOX2 whereas NCCIT, an EC cell line derived from a mediastinal germ cell tumor, has elevated H3K4me3 and H3K27ac for SOX2 and low H3K4me2 and H3K27ac for SOX17 \[96,97\]. TCam-2 expressed SOX17 more than NCCIT. In TCam-2, elimination of an upstream region of SOX17 downregulated POU5F1, NANOG, and LIN28 \[7\].

TCam-2 xenotransplanted to the abdominal flank in mice upregulated NODAL to express EC genes \[97\]. The upregulation of NODAL was mediated through a hypomethylated DNMT3B, GDF3, DPPA3, SOX2, LIN28, and ZIC3.

SE had <1% methylation of CpG/CpH sites whereas EC had frequent CpH methylations \[51\]. Comparing SE and EC, DNMT3B and TET2 were the genes that differed most in expression \[98\]. EC has moderate levels of H3K4me2 and H3K4me3 and no H3K9me2 and H3K27me3.

In EC, an OCT4/SOX2 complex binds to a canonical motif CTTTGTCATGCAAT \[7,92\]. It is located in enhancers of pluripotency genes whereas the compressed motif is located in regulatory regions of genes for differentiation into endoderm structures.

In TCam-2, SOX17 bound more to the compressed motif of OCT4 and SOX2 than to the canonical motif whereas in 2012p, a NST cell type, SOX2 bound equally well to the canonical and compressed motifs. The canonical motif activates GDF3, POU5F1, SALLA, SOX2, and TP53.

In P16 cells, a NST cell type, silencing of OCT4, KLF4, MYC, and NANOG impaired tumor growth \[99\].

Additionally, methylations of H4 arginine can actively regulate expression of genes \[100,101\].

3.2. DNA Methylations

The 5-C methylation of cytosines in the DNA string changes the chromatin structure in DNA from heterochromatin to euchromatin and opens it for gene expression (Supplementary Figure S1). The level of DNA methylation increases as GCNIS progresses through undifferentiated TGCT into differentiated NST. Comparing the TGCT subtypes, the expression of TET was inversely associated with DNA methylation \[82\]. GCNIS and SE did not stain for 5-mC, whereas EC had a moderate staining, and YST, CC, TER, drug-resistant SE, TCam-2, and NS cell lines NT2, 2012p, and NCCIT stained homogenously positive \[102\]. In TGCT, a methylated gene body increases expression of the gene whereas a methylated promoter of the gene inhibits expression of the gene \[103\].

GCNIS expresses both DNMT1, DNMT3A, and DNMT3B \[90\]. For restitution, GCNIS expresses a base excision repair (BER) protein that makes cells reestablish cytosines at abasic sites where the cytosines previously had been eliminated \[104\]. GCNIS has an extremely low level of 5-mC \[20\].

SE overexpresses TET1, has low proportions of 5-mC and 5-mhC, and no CpG methylations at CpG sites \[82\]. SE upregulated TET1, TET2, and TET3 \[82,88\]. SE and EC had median 17% and 31% complete methylations of CpG sites in the upstream region for POU5F1, whereas YST and TER had the methylations in three quarters of the CpG sites \[105\]. SE and differentiated NST expressed MYC, but differed in gene networks and miRNA \[106\].

TCam-2 expressed TET2 more than the NST cell lines NT2, 2012p, and NCCIT \[98\]. Compared with SE, EC had significantly more methylations of promoters of the tumor suppressor genes MCAM \(p < 0.0005\), chi2 test), MGMT \(p < 0.0005\), MLH1 \((p = 0.004)\),
S100 ($p < 0.0005$), VGF ($p = 0.011$, and FKBP4 ($p < 0.0005$) [107]. EC expresses DNMT3B and EHMT2 more than SE [105]. EC has hypermethylated promoters in 40 downregulated genes [71]. Transfection of micro-RNA 630 into a NT2/D2 EC cell line targeting the 3’UTR of POU5F1, SOX2, and NANOG inhibited the expression of the genes [108]. TGCT has methylated repetitive elements in the DNA strand [57]. Differentiated NST had CpG methylation similar to solid cancers [82].

### 3.3. Histone Modifications and Modulations

Methylations and acetylations of histone 3 lysines change DNA structures from heterochromatin to euchromatin and opens them for gene expression (Supplementary Figure S2a,b). Histone modifications also contribute to the TGCT tumorigenesis. In normal germ cells, upregulation of E2F1 in the CCND2/RB1 signal transduction pathway gave rise to atypical mitosis and cell atypia like that in GCNIS [109].

EC had H3K4 and H3K9 methylations [110]. EZH2, enhancer of Zeste-2, is a histone methyltransferase (“writer”) and a catalytic subunit in the polycomb repressor complex 2 (PRC2). EZH2 methylates H3K27, condenses chromatin structure, and silences tumor suppressor genes CDKN2A (p16(INK4)) and RB1 (Figure 3a). Silencing EZH2 with siRNA reduced cellular DNA replication and cell growth. A lysine specific demethylase 1A, KDM1A/LSD1, demethylates H3K4me2 [111].

![Diagram](attachment:image.png)
H3K modifications differ by their binding sites on the genes as they regulate expression of genes. H3K4me3 and H3K27ac activate enhancers whereas H3K4me1 poises enhancers (Figure 3a). Akt-phosphorylated OCT4 stabilized OCT4, facilitated its nuclear localization, and its interaction with SOX2 [112].

Normal testicular tissue highly expresses EZH2 whereas the expression is lower in GCNIS, and further reduced in invasive TGCT [113]. In EC cells, a H3K36 methyltransferase SETD2 trimethylated H3K9, H3K27, and H3K36 on sites in OCT4, SOX2, and NANOG [114]. In 2102p, knockdown of DNMTB increased H3K27me3, EZH2 expression, and sensitivity to cisplatin [114]. TGCT has an antagonism between the regulation with H3K4me3 and H3K27me3. The antagonism gives TGCT a cellular plasticity and supports pluripotency. In POU5F1- and SOX2-positive EC cells, inhibition of LSD1 reduced proliferation whereas LSD1 inhibition of POU5F1- and SOX2-negative EC cells did not change the proliferation [111].

TER moderately expresses H3K4me2, H3K4me3, H3K9me1, H4K9me2, and H3K9me3, whereas YST strongly express the histone marks.

Combined, H3K4me3 and H3K27me3 in promoters of genes generate poised/bivalent signals for expression of genes [115].

3.4. Driver Genes

Epigenetics regulate driver genes in TGCT (Table 1). TCam-2 have low levels of H3K4me3 and H3K27ac whereas NST cell lines have high levels [96]. The driver genes POU5F1, SOX2, LIN28, and NANOG form a network of genes [116]. Upstream of the gene body, POU5F1 has four conserved regions that can bind SOX2, NANOG, and HIF2A (HIF-2α, EPAS1) [117]. Dimethylated promoter for POU5F1 increased expression of POU5F1, whereas reduced methylation reduced expression of the gene [110]. OCT4 binds to the ATTATGCAT motif.
Table 1. Histologic types of TGCT and epigenetic regulation.

<table>
<thead>
<tr>
<th>Expressed Transcription Factors</th>
<th>Histologic Types</th>
<th>NGC</th>
<th>GCNIS</th>
<th>SE</th>
<th>EC</th>
<th>TER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epigenetic mediators</td>
<td>High</td>
<td>PRAME</td>
<td>PRAME, KIT, SOX17, POU5F1, NANOG</td>
<td>PRAME, KIT, SOX17, KLF4, POU5F1, NANOG, MYC, DNMT3B</td>
<td>NANO, POU5F1, POU5F1, DNMT3B</td>
<td>RIB, MYC</td>
</tr>
<tr>
<td>Low</td>
<td></td>
<td>RB1</td>
<td>RB1</td>
<td>RB1, MYC</td>
<td>RB1, MYC</td>
<td>POUS5F1, SOX2, LIN28, NANO</td>
</tr>
<tr>
<td>5mC</td>
<td></td>
<td>+++</td>
<td>Neg</td>
<td>+++</td>
<td>+++</td>
<td>Neg/++</td>
</tr>
<tr>
<td>5mHC</td>
<td></td>
<td>Neg/++</td>
<td>Neg/++</td>
<td>+++</td>
<td>+++</td>
<td>Neg/+</td>
</tr>
</tbody>
</table>

The signs +/++/+++ indicates the degree of positive immunohistochemical stainings.

POU5F1 is expressed in most GCNIS and all SE and EC [118]. NST cell lines have a network between DNMT3B and POU5F1 [119]. Many transcription factors may be involved with the SOX2-OCT4 connection.

TCam-2 has low H3K4me3 and H3K27ac whereas NST cell lines have elevated levels. In EC cells, overexpression of POU5F1 inhibited the expression of NANOG but not the expression of FGF4 and UTF1 [120]. In malignant germ cells, ACT-driven phosphorylation of OCT4 stabilizes OCT4, stimulates its interaction with SOX2, and increases cell survival [112]. Many transcription factors may be involved in the SOX2-OCT4 connection. In EC cell lines, LSD1 inhibition downregulated OCT4 and SOX2 [121].

OCT4-activating compounds (OAC1) activate genes stimulated by POU5F1 and NANOG [122].

In NCCIT cells, siRNA downregulation of POU5F1 reduced expression of SOX2, LIN28, and NANOG, and upregulated genes for differentiation, such as OTX1, HAND1, and LAMBI [123]. In EC cell lines, miRNA-27 inhibited expression of POU5F1 and made the cells differentiate [124]. Downregulation of OCT4 increased miR-27, and the increase of miR-27 down-regulated NANOG [125]. Treatment of an EC cell line with an LSD1 inhibitor downregulated OCT4 and SOX2 [121].

SOX17 is hypomethylated in EC [126]. Deletion of SOX17 reduced expression of POU5F1 [7]. In malignant germ cells, the switch from SOX17 to SOX2 determines whether cells function as SE or EC [127].

Deletion of SOX17 reduced expression of POU5F1. TCam-2 had an elevated H3K4me1 in SOX17 whereas NCCIT had a low level [128]. Methylation of the SOX17 promoter downregulated expression of SOX17 [129]. The SOX17 promoter has 420 base pairs and 48 GpC sites [130].

SOX2 is suppressed in SE by the polycomb repressive complex and H3K27me3 [93]. SE and EC has a hypomethylated SOX2 whereas SOX2 in TER has a higher methylation [131]. TCam-2 needs expression of SOX2 for being reprogrammed into EC [7].

NST cell lines have a network between DNMT3B and POU5F1.
EC expressed SOX2 three times more than TCam-2. In NCCIT cultures, silencing of SOX2 gave prominent cell death within three days [123].

LIN28 has a role in the TGCT tumorigenesis [132]. A distal enhancer of LIN28 has three binding sites for OCT4 [133]. LIN28 mediates effects by downregulated LET-7 microRNA [134]. SiRNA downregulated LIN28 and reduced expression of SOX2 and NANOG. In P19 malignant germ cells, silencing of LIN28 reduced proliferation and tumor formation [132].

Regarding NANOG, Nettersheim et al. denoted a region upstream the transcription start site the NANOG regulatory region (NRR) [135]. It has binding elements for OCT4 and SOX2 [136,137]. Binding of the transcription factors to NRR increases the expression of NANOG whereas methylation of NRR inhibits the transcription factors which are bound to NRR and inhibits the expression of NANOG. GCNIS, SE, and EC express NANOG whereas TER does not [138]. TGCT cell lines with unmethylated NRR express NANOG whereas cell lines with methylated NRR do not. In EC cells, two transactivating domains in the C-terminal region of NANOG mediate expression of NANOG [139].

3.5. Epidrugs and TGCT

Drugs that inhibit epigenetic regulation of gene expression are denoted epidrugs. They have been studied in TGCT (Table 2). In a cohort study of treatment with the methyltransferase (“writer”) inhibitor 5-azacytidine (5-aza), 2 of 4 TGCT patients had partial remission [140]. Another study reported that one of 17 patients with TGCT treated with 5-aza had no evidence of disease at the end of follow-up [141]. In TCam-2, 5-aza increased expression of POU5F1 and NANOG. Trichostatin works synergistically with retinoic acid [142].

### Table 2. Epidrugs in TGCT and other cancers.

<table>
<thead>
<tr>
<th>Pharmacologic Group</th>
<th>Drugs</th>
<th>TGCT Studies Cell lines</th>
<th>Patients</th>
<th>Ref</th>
<th>Other Malignancies</th>
</tr>
</thead>
<tbody>
<tr>
<td>DNMTi</td>
<td>5-aza</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>Myelodysplastic syndromes</td>
</tr>
<tr>
<td></td>
<td>5-aza-cD</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Guadecitabine</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>KDMi</td>
<td>Chaertocin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>JIB-04</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EZH2i</td>
<td>Tazemetostat</td>
<td></td>
<td></td>
<td></td>
<td>Follicular NH lymphoma</td>
</tr>
<tr>
<td>Bromodomaini</td>
<td>JQ11</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LSD1i</td>
<td>CBB3001</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDACi</td>
<td>belinostat</td>
<td>X</td>
<td></td>
<td></td>
<td>Cutaneous T cell lymphoma</td>
</tr>
<tr>
<td></td>
<td>chicamid</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>depsipeptide</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>panobinostat</td>
<td>X</td>
<td></td>
<td></td>
<td>Cutaneous T cell lymphoma</td>
</tr>
<tr>
<td></td>
<td>Romidepsin</td>
<td>X</td>
<td></td>
<td></td>
<td>Cutaneous T cell lymphoma</td>
</tr>
<tr>
<td></td>
<td>Quisinostat</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>trichostatin</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>vorinostat</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDKi</td>
<td>dinaciclib</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Flavo-piridol</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NVP-2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SY0351</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>thal-sns-032</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>THZ1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>THZ531</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>YKL-5-214</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

140
EORTC conducted a trial of NST patients treated with the DNA methylation inhibitor 5-aza-2′-deoxycytidine (5-aza-dC) [145]. The response to 5-aza-dC depended on the cellular expression of POU5F1 and DNMT3B. Treatment with 5-aza-dC increased the expression of DNMT3B. For patients with cisplatin-resistant metastatic TGCT, treatment with cisplatin and an inhibitor of DNA methyltransferase, guadecitabine, did not give long-lasting complete remissions [143].

Epidrugs for TGCT have mainly been evaluated in cell cultures of malignant germ cell lines because most patients with metastatic TGCT are cured with chemotherapy. In the TGCT cell lines NCCIT and 2012p, 5-aza had long-lasting effects [144]. TGCT cell lines have an inverse relation between sensitivity to 5-aza and sensitivity to cisplatin [115]. In EC cells, sensitivity to 5-aza demanded a highly expressed DNMT3B [146,147].

In 1994, Jutterman et al. were the first to report treatment with 5-aza-dC [148]. They found that 5-aza stimulated TCam-2 further and upregulated POU5F1 and NANOG. Three EC cell lines, including Tera-2, were treated with 5-aza [149], and 5-aza-dC demethylated the promoter of POU5F1 and reduced expression of POU5F1 [146,147].

Regarding inhibitors of histone 3 modifications, treatment of an ovarian germ cell tumor cell line PA-1 with an inhibitor of the histone methylase LSD1, CBB3001, downregulated OCT4 and SOX2 and inhibited tumor growth [121]. Treatment of the EC cell line P19 with a histone lysine demethylase (KDM) inhibitor, tranylcypromine, inhibited a histone demethylase, increased H3K4 methylation, and expression of POU5F1 [150]. In addition, a chimeric inhibitor animacroxam was effective [151].

In cisplatin-sensitive and cisplatin-resistant EC cell lines, two inhibitors of histone lysine deacetylase (HCAD), belinostat and panobiotat, were effective [152]. In NST cell lines, also the HDAC inhibitor depsipeptide was effective [153]. A bromodomain inhibitor, JQ1, binds to the amino-terminal twin of bromodomains of BET proteins that bind to acetylated histone lysines. In an EC cell line, JQ1 downregulated pluripotency factors and caused the cells to differentiate into mesodermal structures [154].

Treatment with the HDAC1 inhibitor, romidepsin, increased H3K acetylations and decreased ARIL and thereby expression of POU5F1, SOX2, LIN28, and NANOG [155]. Treatment of the EC cell line P19 with the HDAC inhibitor trichostatin (TSA) inhibits cell progression [121]. A study compared treatment of germ cell tumor cell lines with seven epidrugs [156].

The CDK inhibitor YKL-5-124 inhibited both TCam-2 and 2102p whereas SY0351 and NVP2 gave cell line-specific responses [157].

4. iPSC in Oncology

4.1. TGCT

We confirmed and expanded the role iPSC has for the tumorigenesis of TGCT based on epigenetic regulations of driver genes, not least genes in iPSC panels. Epigenetic mechanisms regulate the shift from an OSKM-like panel in SE to an OSLN panel in EC, and the silencing of the OSLN panel in TER. iPSC genes form a biologic background for the genetic and histologic changes between the TGCT subtypes. DNA methylations and histone modifications regulate iPSC genes. Driver genes reprogram malignant germ cells to pluripotency, increase unlimited self-renewal and independency of growth factors, and inhibit the suppression of proliferation, all hallmarks of malignancy [158].

In 1946, Friedman and Moore were first to point out that EC has a unique toti-differentiation potential which is crucial for the TGCT tumorigenesis [159]. In 1980, Pugh and Parkinson commented on the tumorigenesis and classification of TGCT and noted that clinicians generally lump the TGCT subtypes as SE and NS whereas pathologists generally split TGCT in subtypes [160]. Our review categorizes all TGCT subtypes as a continuum of progression. Correspondingly, oncologists generally treat patients with
stage 1 SE and NST with active surveillance, and treat patients with metastatic SE and NS with BEP chemotherapy.

The evidence regarding the OSKM and OSLN panels motivates an iPSC hypothesis for the TGCT tumorigenesis. The first premise is that iPSC panels can reprogram cells to iPSC and that only iPSC and EC can differentiate into TER. A second premise is that OSKM and OSLN panels can reprogram both normal somatic cells and malignant germ cells into an iPSC/induced totipotent stem cell pattern. Thus, iPSC panels can reprogram cells with normal and abnormal ploidy into iPSC/induced toti-potential cells.

A third premise is that EC expresses the OSLN panel and is able to differentiate into YST, CC, and TER whereas normal somatic cells reprogrammed with the OSKM panel to iPSC only are able to differentiate into TER. Accordingly, the cellular background before reprogramming for iPSC determines the frames for differentiation of iPSC/totipotent cells.

GCNIS develops into MGCT within median five years [161]. The median age at diagnosis for SE patients is 35 years and 25 years for NST patients, so it is more likely that the tumorigenesis of TGCT starts during puberty than during fetal life.

The regional site for xenotransplants of TCam-2 to mice is crucial for progression to EC [8]. The fact points out that the microenvironment governs expression of genes in iPSC panels, mediated by epigenetic mechanisms. Thus our review add an epigenetic dimension to the “genvironmental” hypothesis for the TGCT tumorigenesis proposed by Looijenga [162].

Many observations support the progression from SE to EC. An autopsy series of patients with primary SE showed that 63 (44%) of 145 patients had NST metastases at the time of death [163].

Epigenetics have a key role for the TGCT tumorigenesis, and gene mutations have a limited role. The Genomic Cancer Atlas (TGCA) study of patients with TGCT reported that of TGCT subtypes, only SE had mutations in KIT, KRAS, and NRAS [51]. The shifts in gene expression associated with progression between the TGCT subtypes exclude that mutations in general regulate the expression of the driver genes and the progression of the TGCT subtypes.

The iPSC panels also govern clinical characteristics between the TGCT subtypes. The low SOX2 expression in SE and high SOX2 expression in EC explain why SE mostly is the only TGCT subtype in SE tumors, and why NST TGCT most often incorporates more than one NST subtypes. The transition from SE to EC explains why TGCT often combine SE and NST elements.

The pattern of gene expression also explains why SE proliferates more slowly than EC [164], and why patients with SE have a median age at diagnosis that is ten years higher than that for patients with NST. Furthermore, the switch from SOX17 to SOX2 between the TGCT subtypes explains why SE responds better to platin-based chemotherapy than EC, and why SE is sensitive to radiation therapy in contrast to the radiation-insensitivity of NST subtypes [165]. As EC differentiates into TER, the switch in expression of iPSC genes contributes to the cisplatin-resistance in TER.

Our review includes three driver genes with gene locus on chromosome 12. In addition, reprogramming of TCam-2 to EC also upregulated three genes DPPA3, GDF3, and BCAT1 [97], that also have their gene locus on chromosome 12p.

Several gene networks collaborate in the TGCT tumorigenesis. We report that iPSC genes work synergistically in a network. A second network is the CCND2/RB1 signal transduction pathway, and a third network is genes on the short arm of chromosome 12 associated with anaerobic glycolysis [166]. POUSF1 also participates in a fourth network that links macro-environmental factors such as retinoic acid and cisplatin to a downregulated POUSF1, causing downregulated NOXA and PUMA, and reduced apoptosis [86].

The link between i (12p) and extratubular invasion of malignant germ cells implies that CCND2, NANOG, and LDHB (with gene loci on chromosome 12p) are more important for the progression between the TGCT subtypes than KITL and CDK4 (with gene loci on chromosome 12q).
National and international studies support that S-AFP, S-hCG, and S-LDH are prognostic indicators for TGCT. One of the authors (FEvE) was first to report the prognostic value of S-LDH in 1978, and two multivariate analyses later confirmed the prognostic value [167–169]. The prognostic value of S-LDH was accepted worldwide after the international large collaborative study in 1997 [26]. Recently, the Global Germ Cell Tumor Collaboration documented the prognostic value of S-LDH for patients with advanced SE (hazard ratio 2.9, \( p = 0.003 \)) and patients with NS with intermediate prognosis (hazard ratio 2.6, \( p < 0.001 \)) [170].

As TGCT suppresses LDHC, patients with TGCT and elevated S-LDH do not have detectable S-LDH isoenzyme C [171]. Of present serum tumor markers, only S-LDH-1 is generated from a gene with locus on the short arm of chromosome 12 [172–175].

DATECA studies showed that patients with SE and NST stage 1 had similar good outcomes whether they were treated with radical orchiectomy followed with active surveillance or with adjuvant radiation therapy to pelvic and retroperitoneal lymph nodes [176,177]. Complementarily, DATECA publication of SE and NST TGCT stage 1 followed with surveillance reported that half of the patients had a raised S-LDH-1 before orchiectomy [178,179]. For the NS TGCT patients, a raised S-LDH-1 was associated with a reduced relapse-free survival (\( p = 0.003 \), log-rank test).

Clinically, most patients with metastatic TGCT are cured with a combination of chemotherapy regimen with bleomycin, etoposide, and (cis)platin (denoted BEP) [180]. In addition, some patients are cured with surgery for post-chemotherapy residual TER lesions. Some patients who do not achieve a complete remission with four courses of BEP can be cured with high-dose cisplatin-based chemotherapy [181]. Impressively in recent years, the good five-year overall survival for patient with TGCT improved further [182,183]. The improvement is due to the shift in combination chemotherapy from vinblastine to etoposide in the BEP regimen. For patients with high-risk metastatic TGCT who fail on standard BEP chemotherapy, the decay of two serum tumor markers, S-AFP and S-hCG, pointed to the cisplatin-resistance as early as after the first course of BEP [29,184]. Overall, the prognostic value of the three serum tumor markers is documented in prospective follow-up studies of more than 10,000 patients with TGCT [26,170,182,183].

It is a challenge that patients with metastatic TGCT given a high cumulative dose of cisplatin (>635 mg) have a mortality that increases dramatically after follow-up for ten to twenty years [185]. Accordingly, oncologists might consider to study new systemic treatments as alternative to high-cisplatin-dose chemotherapy.

4.2. Other Malignancies

The driver genes have broad implications in oncology. Small cell lung cancer (SCLC) and small cell esophageal cancer (SCEC) have elevated SOX2 and low RB1 and the two genes reduce inhibition of proliferation [186–188]. Synergy between the two genes explains why SCLC, SCEC, and TGCT grow faster than most other malignancies. Other malignancies also highly express the iPSC panels [189]. iPSC panels, especially SOX2 and the OSN panel, are highly expressed in cancer stem cells of other malignancies [189–192].

POU5F1, SOX2, and NANOG are important for the tumorigenesis of skin, oral squamous, esophageal, lung, and colon cancer [193,194]. SOX2 contributes to the development of brain tumors [195]. NANOG is also an important mediator of cancer induction [196]. For prostate cancer, high expression of SOX2 reduces expression of RB1 and TP53 and changes the cancer from a luminal androgen-receptor-dependent subtype to a basal androgen-receptor-independent subtype [187]. Based on the morphology in prostate cancer, a Gleason score contributes to treatment decisions and predicts outcome of treatment [197]. The increase in Gleason score is denoted as dedifferentiation.

SCLC downregulates both RB1 and TP53 whereas TGCT only downregulates RB1. The difference contributes to different outcomes where most patients with metastatic TGCT are cured with BEP chemotherapy whereas most patients with metastatic SCLC-who despite temporary response to EP-based chemotherapy-progress and die of the cancer.
So far, the United States of America Federal Drug Administration (FDA) has approved seven epidrugs such as 5-aza, 5-aza-cD, belinostat, paninostat, PXD-101, romidepsin, and vorinostat as routine treatment for cutaneous T cell lymphoma, chronic myelomonocytic leukemia (CMML), and multiple myeloma, respectively (Table 2) [198–204]. A phase III trial of patients with myelodysplastic syndrome showed that 5-aza increased overall survival substantially (hazard ratio 0.58, \( p = 0.0001 \), log-rank test) [205]. The FDA also approved a CDK2/CDK6 inhibitor trilaciclib for patients with advanced SCLC treated with EP-containing regimens [206].

In contrast to TGCT, some other malignancies have mutation-based increases in gene expression that are more important than non-mutational increases. Patients with non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR) respond better to targeted systemic treatment with EGFR tyrosine kinase inhibitors (EGFR-TKI) than patients with a high non-mutational expression of EGFR [207]. Today, the best treatments of patients with NSCLC with activating EGFR mutations are third-generation EGFR TKI rosiglitazinib and a combination of first-generation EGFR TKI and chemotherapy [208].

5. Perspectives and Conclusions

Continued research may further expand the knowledge of epigenetic regulation of driver genes in oncology and of the TGCT tumorigenesis. In reprogramming cells for iPSC, other genes can substitute for the genes we report in our review [209,210]. These genes may also be relevant in TGCT tumorigenesis. Thus, the number of relevant driver genes in oncology and in the TGCT tumorigenesis may increase in future. New insight in regulation of TGCT driver genes may also be relevant for other malignancies.

Innovative studies of driver genes in many malignancies have general oncologic relevance. For women with hormone-sensitive breast carcinoma, present epidrugs enhance effects of hormone treatment but also increase adverse effects [211]. The findings motivate new epidrugs with fewer adverse effects.

Investigations of epidrugs in TGCT cell lines have been inspired by the clinical achievements with epidrugs in other malignancies. Recent trials support combinations of epidrugs. For elder patients with acute myeloid leukemia, treatment with a combination of 5-aza and the BCL2 inhibitor venetoclax gave a better overall survival than monotherapy with only 5-aza [212]. Another study showed a synergy between a DNMT inhibitor and a HDAC inhibitor [213].

In addition to serum tumor markers, liquid biopsies monitoring hypermethylated driver genes may improve follow-up routines of patients with TGCT and other malignancies [214].

In TGCT, downregulated tumor suppressor gene RASSF1A increases proliferation [110,215]. TGCT also has a downregulated RB1 [216]. It remains to be shown whether the two tumor suppressor genes act in synergy. A recent review pointed to three genes with gene locus on the short arm of chromosome 12, GLUT3, GAPDH, and TPII, that participate in anaerobic glycolysis [166]. The question remains whether LDHB and the three genes collaborate for a Warburg effect in TGCT [217,218].

For patients with TGCT, the target and timing may increase the efficacy of epidrugs. New epidrugs might specifically target the motifs of the combinations of OCT4 and SOX2/SOX17. As for more upfront timing, new trials may recruit patients with high-risk metastatic NS and limited decay of S-AFP and S-hCG after the first course of BEP. Such trials can investigate the efficacy of BEP combined with relevant candidate drugs as alternative to high-dose cisplatin chemotherapy (Figure 4).
of 5-aza and the BCL2 inhibitor venetoclax gave a better overall survival than monotherapy with only 5-aza [212]. Another study showed a synergy between a DNMT inhibitor and a HDAC inhibitor [213].

In addition to serum tumor markers, liquid biopsies monitoring hypermethylated driver genes may improve follow-up routines of patients with TGCT and other malignancies [214].

In TGCT, downregulated tumor suppressor gene RASSF1A increases proliferation [110,215]. TGCT also has a downregulated RB1 [216]. It remains to be shown whether the two tumor suppressor genes act in synergy. A recent review pointed to three genes with gene locus on the short arm of chromosome 12, GLUT3, GAPDH, and TPII, that participate in anaerobic glycolysis [166]. The question remains whether LDHB and the three genes collaborate for a Warburg effect in TGCT [217,218].

For patients with TGCT, the target and timing may increase the efficacy of epidrugs. New epidrugs might specifically target the motifs of the combinations of OCT4 and SOX2/SOX17. As for more upfront timing, new trials may recruit patients with high-risk metastatic NS and limited decay of S-AFP and S-hCG after the first course of BEP chemotherapy. Such trials can investigate the efficacy of BEP combined with relevant candidate drugs as alternative to high-dose cisplatin chemotherapy (Figure 4).

In conclusion, genes that reprogram for iPSC have a major role in the TGCT tumorigenesis, and contribute to the aggressiveness in many other malignancies.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms24044148/s1.

Author Contributions: Conceptualization: F.E.v.E. and F.F.N. methodology: K.K. conducted research on gene expression of LDHB in TGCT. R.H. contributed on presentation of MGCT. O.P. conducted immunohistochemistry for EC. writing the initial draft: F.E.v.E. rewriting: F.E.v.E., D.S.K. and F.F.N. funding acquisition: F.E.v.E. supervision: D.S.K., F.F.N. and K.K. All authors have read and agreed to the published version of the manuscript.

Funding: Minister Erna Hamiltons Foundation for art and sciences.

Acknowledgments: The authors thank Rachel Eiges. Shaale Zetek Medical Center, Jerusalem, Israel. rachela@szmc.org.il, for a figure of iPSC for the published case of iPSC for a 32 year old man with SE. The authors are very grateful for a grant from minister Erna Hamilton’s foundation for art and science.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFP</td>
<td>alfa fetoprotein</td>
</tr>
<tr>
<td>5-aza</td>
<td>5-azacytidine</td>
</tr>
<tr>
<td>5-aza-cD</td>
<td>5-aza-2′-deoxycytidine</td>
</tr>
<tr>
<td>BEP</td>
<td>bleomycin, etoposide, and (cis)platin</td>
</tr>
<tr>
<td>bromodomaini</td>
<td>bromodomain inhibitor</td>
</tr>
<tr>
<td>CC</td>
<td>choriocarcinoma</td>
</tr>
<tr>
<td>CDK</td>
<td>cyclin D kinase</td>
</tr>
<tr>
<td>CDKi</td>
<td>CDK inhibitor</td>
</tr>
<tr>
<td>CYT</td>
<td>spermatocyte</td>
</tr>
<tr>
<td>DNMT</td>
<td>DNA methyltransferase</td>
</tr>
<tr>
<td>DATECA</td>
<td>the Danish testis cancer study group</td>
</tr>
</tbody>
</table>
DNMT DNA methyl transferase
DNMTi DNA methyltransferase inhibitor
EC embryonal carcinoma
EGFR epidermal growth factor receptor
ESC embryonic stem cells
EZH2 enhancer of Zeste-2
EZH2i EZH2 inhibitor
GCNIS germ cell neoplasia in situ
GON gonocytes
HAT histone acetylase
hCG human chorionic gonadotropin
HDAC histone deacetylase
HDACi histone deacetylase inhibitor
HDMT histone demethylase
HMT histone methyltransferase
iPSC induced pluripotent stem cells
KDM lysine demethylase
KDMi lysine demethylase inhibitor
Kmt methylated histone 3 lysine
LDH Lactate dehydrogenase
LSD1i LSD1 inhibitor
5mC 5-methyl cytosine
5mhC 5-methylhydroxy cytosine
MGCT microinvasive germ cell tumor
NGC normal germ cells
NSCLC non-small cell lung cancer
NST non-seminomatous germ cell tumor
OCT4 the protein of POU5F1
OSKM the OCT4, SOX2, KLF4, and MYC panel
OSLN the OCT4, SOX2, LIN28, and NANOG panel
PGC primordial germ cells
PRC2 polycomb repressor complex 2
SCLC small cell lung cancer
SEC small cell esophageal cancer
SE seminoma
SPA spermatogonia type A
SPB spermatogonia type B
TER teratoma
TET DNA demethylase
TGCA The Genomic Cancer Atlas
TKI tyrosine kinase inhibitor
TNM international tumor, nodes, and metastases classification
TSS transcription start site.
WHO World Health Organization
YST yolk sac tumor

References
4. Gutierrez-Aranda, I.; Ramos-Mejia, V.; Bueno, C.; Munoz-Lopez, M.; Real, P.J.; Macia, A.; Sanchez, L.; Ligero, G.; Garcia-Perez, J.L.; Menendez, P. Human induced pluripotent stem cells develop teratoma more efficiently and faster than human embryonic stem cells regardless the site of injection. Stem Cells 2010, 28, 1568–1570. [CrossRef]


24. von Eyben, F.E.; Parraga-Alava, J.; Tu, S.M. Testicular germ cell tumors type 2 have high RNA expression of LDHB, the gene for lactate dehydrogenase subunit B. *Asian J. Androl.* 2021, 23, 357–362. [CrossRef]


34. Trabert, B.; Sigurdson, A.J.; Sweeney, A.M.; Amato, R.J.; Strom, S.S.; McGlynn, K.A. Baldness, acne and testicular germ cell tumours. *Int. J. Androl.* 2011, 34, e59–e67. [CrossRef]


36. Teilum, G. Endodermal sinus tumors of the ovary and testis. Comparative morphogenesis of the so-called mesoepothema ovarii (Schiller) and extraembryonic (yolk sac-allocentric) structures of the rat’s placenta. *Cancer* 1959, 12, 1092–1105. [CrossRef]


49. Yan, X.; Cao, L.; Li, Q.; Wu, Y.; Zhang, H.; Saiyin, H.; Liu, X.; Zhang, X.; Shi, Q.; Yu, L. Aurora C is directly associated with Survivin and required for cytokinesis. Genes Cells 2005, 10, 617–626. [CrossRef]


56. Godmann, M.; Gashaw, I.; Eildermann, K.; Schweyer, S.; Bergmann, M.; Skotheim, R.I.; Behr, R. The pluripotency transcription factor Kruppel-like factor 4 is strongly expressed in intratubular germ cell neoplasia unclassified and seminoma. J. Urol. 2003, 169, 1376–1383. [CrossRef]


59. Yan, X.; Cao, L.; Li, Q.; Wu, Y.; Zhang, H.; Saiyin, H.; Liu, X.; Zhang, X.; Shi, Q.; Yu, L. Aurora C is directly associated with Survivin and required for cytokinesis. Genes Cells 2005, 10, 617–626. [CrossRef]


76. Ottesen, A.M.; Skakkebæk, N.E.; Lundsteen, C.; Leffers, H.; Larsen, J.; Rajpert-De Meyts, E. High-resolution comparative genomic hybridization detects extra chromosome arm 12p material in most cases of carcinoma in situ adjacent to overt germ cell tumors, but not before the invasive tumor development. *Genes Chromosomes Cancer* 2003, 38, 117–125. [CrossRef]


84. Norgaard-Pedersen, B.; Albrechtsen, R.; Teilum, G. Serum alpha-foetoprotein as a marker for endodermal sinus tumour (yolk sac tumour) or a vitelline component of “teratocarcinoma”. *Mol. Carcinog.* 2017, 56, 1837–1850. [CrossRef]


89. Liu, J.; Shi, H.; Li, X.; Chen, G.; Larsson, C.; Lui, W.O. miR2233p regulates cell growth and apoptosis via FBXW7 suggesting an oncogenic role in human testicular germ cell tumors. *Int. J. Oncol.* 2017, 50, 356–364. [CrossRef]


91. Kristensen, D.G.; Skakkebaek, N.E.; Rajpert-De Meyts, E.; Almstrup, K. Epigenetic features of testicular germ cell tumours in relation to epigenetic characteristics of foetal germ cells. *Int. J. Dev. Biol.* 2013, 57, 309–317. [CrossRef]


110. Lambrot, R.; Kimmins, S. Histone methylation is a critical regulator of the abnormal expression of POUSF1 and RASSF1A in testis cancer cell lines. Int. J. Androl. 2011, 34, 110–123. [CrossRef]


119. Wongtrakongvate, P. Epigenetic therapy of cancer stem and progenitor cells by targeting DNA methylation machineries. World J. Stem Cells 2015, 7, 137–148. [CrossRef]


128. Van Der Zwan, Y.G.; Stoop, H.; Rossello, F.; White, S.J.; Looijenga, L.H. Molecular and epigenetic pathogenesis of germ cell tumors: A morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas. Mod. Pathol. 2009, 22, 1066–1074. [CrossRef]


134. Van Der Zwan, Y.G.; Stoop, H.; Rossello, F.; White, S.J.; Looijenga, L.H. Molecular and epigenetic pathogenesis of germ cell tumors: A morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas. Mod. Pathol. 2009, 22, 1066–1074. [CrossRef]


159. Friedmann, N.B.; Moore, R.A. Tumors of the testis; a report on 922 cases. Mil. Surg. 1946, 99, 573–593. [CrossRef]


Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.